These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 28434396)
41. Immune-Checkpoint Blockade Therapy in Lymphoma. Kuzume A; Chi S; Yamauchi N; Minami Y Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706 [TBL] [Abstract][Full Text] [Related]
42. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419 [TBL] [Abstract][Full Text] [Related]
44. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. Li TJ; Wang WQ; Yu XJ; Liu L Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324 [TBL] [Abstract][Full Text] [Related]
45. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. Tintelnot J; Stein A World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527 [TBL] [Abstract][Full Text] [Related]
46. Immunotherapy for hepatocellular carcinoma. Zongyi Y; Xiaowu L Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905 [TBL] [Abstract][Full Text] [Related]
47. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Hayashi H; Nakagawa K Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270 [TBL] [Abstract][Full Text] [Related]
49. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Loo K; Daud AI Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249 [TBL] [Abstract][Full Text] [Related]
50. Revisiting Immunotherapy: A Focus on Prostate Cancer. Cha HR; Lee JH; Ponnazhagan S Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566 [TBL] [Abstract][Full Text] [Related]
51. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology. Mihăilă RG Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510 [TBL] [Abstract][Full Text] [Related]
52. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Jiang Y; Chen M; Nie H; Yuan Y Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929 [TBL] [Abstract][Full Text] [Related]
54. Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Calabrò L; Ceresoli GL; D'Incecco A; Scherpereel A; Aerts J; Maio M Cytokine Growth Factor Rev; 2017 Aug; 36():25-31. PubMed ID: 28736182 [TBL] [Abstract][Full Text] [Related]
55. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma? Dhariwal R; Pindoria N; Dasgupta P; Khan MS BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606 [No Abstract] [Full Text] [Related]
56. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. Shen C; Zhang Z; Zhang Y Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182 [TBL] [Abstract][Full Text] [Related]
57. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies. Rallis KS; Hillyar CRT; Sideris M; Davies JK Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705 [TBL] [Abstract][Full Text] [Related]
58. Immunotherapy in gynecological cancers: where are we? Polastro L; Closset C; Kerger J Curr Opin Oncol; 2020 Sep; 32(5):459-470. PubMed ID: 32675594 [TBL] [Abstract][Full Text] [Related]